Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rezolute (NASDAQ: RZLT) announced an inducement equity grant for two new employees, approved under Nasdaq Listing Rule 5635(c)(4).
The company granted options to purchase a total of 245,000 shares of common stock, with a 10-year term and an exercise price of $9.32 per share (closing price on October 31, 2025). The options vest over four years, subject to continued service.
Rezolute (NASDAQ: RZLT) ha annunciato un inducement equity grant per due nuovi dipendenti, approvato ai sensi della Nasdaq Listing Rule 5635(c)(4).
L'azienda ha concesso opzioni per l'acquisto di un totale di 245.000 azioni ordinarie, con un termine di 10 anni e un prezzo di esercizio di 9,32 dollari per azione (prezzo di chiusura al 31 ottobre 2025). Le opzioni maturano nell'arco di quattro anni, soggette al proseguimento della funzione.
Rezolute (NASDAQ: RZLT) anunció una asignación de acciones por inducement para dos nuevos empleados, aprobada bajo la Regla 5635(c)(4) de Nasdaq Listing.
La empresa otorgó opciones para comprar un total de 245.000 acciones comunes, con un plazo de 10 años y un precio de ejercicio de $9.32 por acción (precio de cierre al 31 de octubre de 2025). Las opciones se consolidan durante cuatro años, sujetas a la continuidad del servicio.
Rezolute (NASDAQ: RZLT)는 두 명의 신규 직원에게 유인 주식 부여를 발표했으며, 나스닥 상장 규칙 5635(c)(4)에 따라 승인되었습니다.
회사 는 총 245,000주의 보통주를 매입할 수 있는 옵션을 부여했으며, 10년의 기간과 주당 행사 가격 $9.32를 갖습니다(2025년 10월 31일 종가 기준). 옵션은 4년에 걸쳐 취득되며, 지속적인 서비스에 의존합니다.
Rezolute (NASDAQ: RZLT) a annoncé une attribution d’actions pour inducement pour deux nouveaux employés, approuvée selon la règle Nasdaq Listing 5635(c)(4).
L’entreprise a accordé des options d’achat d’un total de 245 000 actions ordinaires, avec une période de 10 ans et un prix d’exercice de $9,32 par action (prix de clôture au 31 octobre 2025). Les options vestent sur une période de quatre ans, sous réserve d’un maintien du service.
Rezolute (NASDAQ: RZLT) kündigte eine Inducement-Aktienzuteilung für zwei neue Mitarbeiter an, genehmigt gemäß Nasdaq Listing Rule 5635(c)(4).
Das Unternehmen hat Optionen zum Kauf von insgesamt 245.000 Stammaktien gewährt, mit einer 10-Jahres-Frist und einem Ausübungspreis von $9,32 pro Aktie (Schlusskurs am 31. Oktober 2025). Die Optionen vesten über vier Jahre, vorbehaltlich der weiteren Dienstleistung.
Rezolute (NASDAQ: RZLT) أعلنت عن منحة أسهم تحفيزية لاثنين من الموظفين الجدد، وموافَق عليها بموجب قاعدة إدراج ناسداك 5635(c)(4).
منحت الشركة خيارات لشراء ما مجموعه 245,000 سهمًا من الأسهم العادية، مع مدة عشر سنوات وسعر ممارسة قدره $9.32 للسهم (سعر الإغلاق في 31 أكتوبر 2025). تتفعل الخيارات على مدى أربع سنوات، رهناً باستمرار الخدمة.
- None.
- None.
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted as of October 31, 2025 equity inducement awards to two new employees. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Rezolute.
The Company granted options to purchase 245,000 shares, in the aggregate, of Rezolute common stock to the new employees. The options have a 10-year term and an exercise price per share equal to
Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in the Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Rezolute Contacts:
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
Carrie McKim
cmckim@rezolutebio.com
336-608-9706
FAQ
What did Rezolute (RZLT) grant on October 31, 2025?
What is the exercise price and term for the RZLT inducement options?
How do the RZLT options vest and what is the vesting period?
Under which Nasdaq rule were Rezolute's (RZLT) inducement awards approved?
How many employees received the Rezolute (RZLT) inducement awards?
Does the RZLT press release state any change to guidance or financial results?
